Cellectis SA (CLLS NASDAQ) stock market data APIs
$1.5622
-0.05(-3.2%)
as of July 1, 2025
Try our APIs with
free plan!
Cellectis SA Financial Data Overview
Price chart is built with
Anychart
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Prev. Close
1.5622
Open
1.5076
High
1.618
Low
1.5076
52 wk Range
1.1-2.43
Market Cap
147 M
Shares Outstanding
72 325 K
Revenue
54 747 K
EPS
-0.17
Beta
3.199
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cellectis SA data using free add-ons & libraries
Get Cellectis SA Fundamental Data
Cellectis SA Fundamental data includes:
- Net Revenue: 54 747 K
- EBITDA: -41 047 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cellectis SA News
New
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis. Cash and Cash Equivalents: $264 million as of December 31, 2024, compared to $156 million as of D...
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, toda...
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis Inc. NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-e...
Monthly information on share capital and company voting rights
Cellectis Inc. (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Da...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
